• Rehab Badawi, Naglaa Samy Fahmy Abou Taira, Sara Essam Hasby, Walaa Elkhalawany, Waleed Elrefaey, Nahla Ahmed Khalf, and Ibrahim OkdaHanaaHFrom the Department of Tropical Medicine and Infectious Diseases (Badawi, Elkhalawany, Khalf); from the Department of Internal Medicine (Elrefaey, Okda); and from the Department of Radiology (Abou Taira, Hasby), Faculty of Medicine, Tant.
• From the Department of Tropical Medicine and Infectious Diseases (Badawi, Elkhalawany, Khalf); from the Department of Internal Medicine (Elrefaey, Okda); and from the Department of Radiology (Abou Taira, Hasby), Faculty of Medicine, Tanta University, Tanta, Egypt.
• Saudi Med J. 2024 Oct 1; 45 (10): 103410401034-1040.

ObjectivesTo examine the relation between liver fibrosis and chronic kidney disease (CKD) in metabolic-associated fatty liver disease (MAFLD) patients and its risk factors.MethodsThe current study was carried out at Tanta University Hospital, Tanta, Egypt, from May 2021 to January 2023 and included 84 MAFLD patients with CKD and 80 MAFLD patients without CKD. All participants had been examined by abdominal ultrasonography and transient elastography with controlled attenuation parameter.ResultsChronic kidney disease patients exhibited a greater incidence of fibrosis compared to patients without CKD (75.6% vs. 24.4%). Logistic analysis demonstrated that the presence of multiple health conditions, such as MAFLD, diabetes mellitus, hypertension, and cardiovascular disease, were individually linked to CKD. Gender and body mass index were not independent factors related to CKD. Additionally, factors such as age, hyperuricemia, hypertriglyceridemia, hypercholesterolemia, hypoalbuminemia, hyperbilirubinemia, and viral hepatitis, apart from MAFLD comorbidities, were independently linked to CKD.ConclusionChronic kidney disease may represent a potential risk influence for liver fibrosis development in MAFLD patients.Copyright: © Saudi Medical Journal.

27 keywords...

hide…